psilocybin
Spotlight: Depression remission endures 5 years after psilocybin trial consisting of psilocybin with psychotherapy (2025)
"when it comes to reducing depression with psychedelic-assisted therapy, what matters even more than the drug is a strong relationship between the therapist and study participant."
dmt
Spotlight: N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences (Vohryzek, et al, 2025)
"the connectome harmonic repertoire under N,N-dimethyltryptamine (DMT) is reshaped in line with other reported psychedelic compounds - psilocybin, lysergic acid diethylamide (LSD) and ketamine... the repertoire entropy of connectome harmonics increases under DMT, as with those other psychedelics."
mdma
Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology (Wittenkeller, et al, 2025)
"enhancing baseline dopamine while minimising excessive drug-induced dopamine surges may help normalise motivational circuits and reduce relapse risk."
research
Spotlight: Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial (McGowan, et al, 2025)
"In this trial, COMP360 psilocybin administered in a single session with psychological support was found to be generally well-tolerated and without serious risk to safety... treatment associated with rapid, sustained reduction in PTSD symptoms, improved functioning and quality of life to 12 weeks"
ketamine
Spotlight: Brain changes associated with depression treatment: a meta-analysis
Meta-analysis of data from 302 depressed subjects yielding 87 foci across 18 experiments examining various depression treatments including pharmacology, psychotherapy, electroconvulsive therapy, psilocybin, and ketamine with brain activity measures in response to emotion tasks in the scanner.
cancer
Spotlight: Long-term benefits of single-dose psilocybin in depressed patients with cancer (Agrawal, et al, 2025)
"These findings demonstrate robust antidepressive activity from a single 25 mg dose of psilocybin combined with psychotherapy and suggest a potentially paradigm-changing alternative to traditional antidepressants requiring further study."
ketamine-assisted psychotherapy
Psychedelics in Palliative Care, Marcia Glass, Ed., Oxford University Press
with contributions by Psychedelic Institute fellows, Michael DeMarco, PhD and Thaís Salles Araujo, MD on ketamine, psilocybin mushrooms in palliative care
